[go: up one dir, main page]

DK2001891T3 - Buprenorphine derivatives and their applications - Google Patents

Buprenorphine derivatives and their applications

Info

Publication number
DK2001891T3
DK2001891T3 DK07732177.6T DK07732177T DK2001891T3 DK 2001891 T3 DK2001891 T3 DK 2001891T3 DK 07732177 T DK07732177 T DK 07732177T DK 2001891 T3 DK2001891 T3 DK 2001891T3
Authority
DK
Denmark
Prior art keywords
applications
buprenorphine derivatives
buprenorphine
derivatives
Prior art date
Application number
DK07732177.6T
Other languages
Danish (da)
Inventor
Christopher Bourne Chapleo
John William Lewis
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK2001891T3 publication Critical patent/DK2001891T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07732177.6T 2006-03-28 2007-03-27 Buprenorphine derivatives and their applications DK2001891T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof
PCT/GB2007/001120 WO2007110636A1 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
DK2001891T3 true DK2001891T3 (en) 2013-11-04

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07732177.6T DK2001891T3 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and their applications

Country Status (21)

Country Link
US (1) US7964610B2 (en)
EP (1) EP2001891B1 (en)
JP (1) JP5167446B2 (en)
KR (1) KR101430626B1 (en)
CN (2) CN101410402A (en)
AU (1) AU2007231133B2 (en)
BR (1) BRPI0709157A8 (en)
CA (1) CA2647417C (en)
DK (1) DK2001891T3 (en)
ES (1) ES2432169T3 (en)
GB (1) GB0606124D0 (en)
IL (1) IL193917A (en)
MX (1) MX2008011984A (en)
MY (1) MY151025A (en)
NZ (1) NZ570997A (en)
PL (1) PL2001891T3 (en)
PT (1) PT2001891E (en)
RU (1) RU2435773C2 (en)
TW (1) TWI501969B (en)
WO (1) WO2007110636A1 (en)
ZA (1) ZA200807614B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036980A1 (en) 2006-09-22 2008-03-27 Alltranz Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
PL2307420T3 (en) * 2008-04-24 2012-04-30 Janssen Pharmaceutica Nv Nalmefene di-ester prodrugs
FR2975912B1 (en) 2011-05-30 2013-06-14 Flamel Tech Sa CONTROLLED RELEASE COMPOSITION OF BUPRENORPHINE
MX2018004835A (en) * 2015-10-26 2018-08-01 Orphomed Inc Ethylene glycol ether of buprenorphine.
JP2019507783A (en) 2016-03-09 2019-03-22 エムダブリュ エンキャップ リミテッド Abuse prevention pharmaceutical preparation
PT3512518T (en) 2016-09-13 2023-01-27 Alar Pharmaceuticals Inc Sustained-release buprenorphine formulations background of invention
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab New pharmaceutical compositions
NZ766474A (en) * 2018-05-11 2023-03-31 Alar Pharmaceuticals Inc Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (en) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 Preparation method of thiohydroxy acetic anhydride

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (en) 1996-05-28 1999-06-15 강재헌 A novel analgesic compounds having buprenorphine structure
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
DK1131059T3 (en) 1998-11-13 2003-06-30 Jago Res Ag Dry powder for inhalation
SI1299104T1 (en) 2000-02-08 2009-10-31 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1429730A4 (en) 2001-09-26 2010-06-16 Penwest Pharmaceuticals Compan Opioid formulations having reduced potential for abuse
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ATE444296T1 (en) * 2002-10-25 2009-10-15 Euro Celtique Sa ANALOGUE AND PRODRUGS OF BUPRENORPHINE
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
DE10250087A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
RU2215741C1 (en) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" N-substituted 14-hydroxymorphinane esters and method for their preparing
CN1263760C (en) 2002-11-12 2006-07-12 财团法人奇美医院 Novel buprenorphine ester derivative and its preparation method, and long-acting analgesic pharmaceutical composition
EP1422230B1 (en) * 2002-11-25 2007-12-26 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions
JP2004175706A (en) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine, their preparation, and long-acting analgesic drug compositions
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US7501113B2 (en) 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
US7195882B2 (en) 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Also Published As

Publication number Publication date
BRPI0709157A8 (en) 2018-04-24
CA2647417A1 (en) 2007-10-04
KR20080105124A (en) 2008-12-03
AU2007231133A1 (en) 2007-10-04
EP2001891B1 (en) 2013-07-24
KR101430626B1 (en) 2014-08-18
TWI501969B (en) 2015-10-01
JP2009531406A (en) 2009-09-03
CN104151320A (en) 2014-11-19
CN101410402A (en) 2009-04-15
PL2001891T3 (en) 2014-03-31
BRPI0709157A2 (en) 2011-06-28
TW200806672A (en) 2008-02-01
AU2007231133A2 (en) 2008-10-16
GB0606124D0 (en) 2006-05-03
PT2001891E (en) 2013-10-30
RU2435773C2 (en) 2011-12-10
WO2007110636A1 (en) 2007-10-04
AU2007231133A8 (en) 2011-08-25
ZA200807614B (en) 2009-10-28
EP2001891A1 (en) 2008-12-17
AU2007231133B2 (en) 2011-09-01
IL193917A (en) 2014-12-31
ES2432169T3 (en) 2013-12-02
NZ570997A (en) 2011-08-26
US7964610B2 (en) 2011-06-21
RU2008142527A (en) 2010-05-10
MY151025A (en) 2014-03-31
US20100234412A1 (en) 2010-09-16
CA2647417C (en) 2014-09-23
MX2008011984A (en) 2008-10-03
JP5167446B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
BRPI0716300A2 (en) ARTICLE AND MIX
DK2001891T3 (en) Buprenorphine derivatives and their applications
BRPI0716500A2 (en) PROJECT AND PROJECT DIRECTION METHOD
EP2087096A4 (en) MODIFIED CYANOBACTERY
ATE475662T1 (en) DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES
ATE483711T1 (en) SPIROINDOLINONE DERIVATIVES
DE602007012130D1 (en) MODIFIED FLAVIN-ADENINE-DINUCLEOTIDE-DEPENDENT GLUCOSE-DEHYDROGENASE
ATE469905T1 (en) PYRIDOPYRIMIDINONE DERIVATIVES
BRPI0815588A2 (en) POLYORGANOSYLOXAN-POLYURERIA AND / OR POLYORGANOSYL-XANO-POLYURETHANE COMPOUNDS
ATE512135T1 (en) SPIROINDOLINONE DERIVATIVES
DE602007002544D1 (en) NUANCIERUNGSMITTEL
HRP20141261T1 (en) TIONINIUM COMPOUNDS AND THEIR USES
DE502007001629D1 (en) RFAHREN
DK2086968T3 (en) 5-hydroxymethyl-oxazolidin-2-one derivatives
BRPI0817844A2 (en) 3-Alkoxy-1-phenylpyrazole derivatives and pesticides
CR10430A (en) AMINOTHIAZOLES AND THEIR USES
EP2044097A4 (en) MODIFIED RIBONUCLEASES
DE502006006067D1 (en) NG
EP2054074A4 (en) MODIFIED ERYTHROPOIETINE
DK2068922T3 (en) Anti-IL-13Ralfa1 antibodies and their applications
FI20060665A0 (en) deviation detection
DE602006011371D1 (en) INFRARED EINDRINGDETEKTIONSEINRICHTUNG
EP2191283A4 (en) TIME RANGE REFLECTION METHOD AND USE METHOD
DE112008004261A5 (en) Schichtabscheidevorrichtung and Schichtabscheideverfahren
ES1067357Y (en) TURNING AND ROTATING HAM